{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039219","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.899603+00:00","generated_at":"2026-05-26T01:39:38.012956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M","bullets":["FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.","Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.","Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).","Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039219","json":"https://secwatch.observer/filing/0001193125-25-039219.json","markdown":"https://secwatch.observer/filing/0001193125-25-039219.md","text":"https://secwatch.observer/filing/0001193125-25-039219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/0001193125-25-039219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525039219/d933582d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:39:38.012956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}